Payment overview · 2025
General Payments
$826.96
31 reported records · 13 companies
Healthcare provider profile · identity verified
Daniel C Hood, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BATTLE CREEK, MI · NPI 1639127970
Verified facts
What the public records show
CMS Open Payments records show Daniel C Hood, M.D. received $826.96 in general payments during 2025 across 31 reported records.
Alexion Pharmaceuticals, Inc. accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Nurtec Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $242.10 | 29.3% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $109.70 | 13.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $94.10 | 11.4% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $72.20 | 8.7% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $69.17 | 8.4% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $54.26 | 6.6% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.69 | 5.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.99 | 4.7% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$31.06 | 3.8% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.13 | 2.6% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $19.49 | 2.4% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $17.49 | 2.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.58 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $826.96 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $94.10 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $89.76 | 1 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $69.43 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $69.17 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $54.26 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $41.69 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $40.26 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.99 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.99 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $31.06 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
43 | 16 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 459 | 98 |
| Topiramate | Topiramate | 324 | 56 |
| Levetiracetam | Levetiracetam | 317 | 76 |
| Primidone | Primidone | 164 | 34 |
| Baclofen | Baclofen | 153 | 29 |
| Donepezil Hcl | Donepezil Hcl | 149 | 38 |
| Oxcarbazepine | Oxcarbazepine | 149 | 31 |
| Lamotrigine | Lamotrigine | 137 | 20 |
| Pregabalin | Pregabalin | 132 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 130 | 40 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 107 | 24 |
| Rivastigmine | Rivastigmine | 107 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 24 |
| Memantine Hcl | Memantine Hcl | 94 | 24 |
| Dalfampridine Er | Dalfampridine | 87 | 12 |
| Zonisamide | Zonisamide | 72 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 68 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 68 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | suppressed |
| Tegretol Xr | Carbamazepine | 50 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 12 |
| Trazodone Hcl | Trazodone Hcl | 49 | 13 |
| Memantine Hcl Er | Memantine Hcl | 48 | 14 |
| Dilantin | Phenytoin Sodium Extended | 46 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Teriflunomide | Teriflunomide | 46 | suppressed |
| Clonazepam | Clonazepam | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | 15 |
| Nurtec Odt | Rimegepant Sulfate | 43 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 43 | suppressed |
| Carbamazepine | Carbamazepine | 40 | suppressed |
| Lacosamide | Lacosamide | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 13 |
| Diazepam | Diazepam | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 36 | suppressed |
| Levetiracetam Er | Levetiracetam | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 13 |
| Ropinirole Er | Ropinirole Hcl | 35 | 11 |
| Carbamazepine Er | Carbamazepine | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Modafinil | Modafinil | 27 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 27 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 23 | suppressed |
| Azathioprine | Azathioprine | 22 | suppressed |
| Copaxone | Glatiramer Acetate | 22 | suppressed |
| Depakote | Divalproex Sodium | 22 | suppressed |
| Qulipta | Atogepant | 22 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 21 | suppressed |
| Valproic Acid | Valproic Acid | 21 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Austedo Xr | Deutetrabenazine | 19 | suppressed |
| Lamictal | Lamotrigine | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Kesimpta Pen | Ofatumumab | 18 | suppressed |
| Lorazepam | Lorazepam | 17 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 15 | suppressed |
| Topiramate Er | Topiramate | 15 | suppressed |
| Depakote Er | Divalproex Sodium | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Fingolimod | Fingolimod Hcl | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Tetrabenazine | Tetrabenazine | 12 | suppressed |
| Ampyra | Dalfampridine | 11 | suppressed |
| Aubagio | Teriflunomide | 11 | suppressed |
| Keppra Xr | Levetiracetam | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $826.96 · 31 records | Alexion Pharmaceuticals, Inc. | BRIUMVI, Briviact, HYQVIA, Hizentra, KESIMPTA, Leqembi, Mavenclad, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus Zunovo, PONVORY, ULTOMIRIS, VALTOCO, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error